Fundraising Fox

Jeff Goater

Investor

Partner at The Column Group

Boston, Massachusetts

Writes $100K – $5M checks Β· typically $1.5M

About

Jeff Goater leverages a career from research scientist to Evercore investment banker to biotech CEO, bringing deep technical, company-building expertise and a hands-on style as executive chair or interim CEO.

Invests in

BiotechHealthtech

Experience

  1. Judo BioBoard Membercurrent2026 β€” present
  2. Judo BioExecutive Chair2022 β€” 2026
  3. Tortugas NeuroscienceBoard Membercurrent2025 β€” present
  4. NILO TherapeuticsBoard Membercurrent2024 β€” present
  5. Kenai TherapeuticsBoard Membercurrent2024 β€” present
  6. The Column GroupPartnercurrent2024 β€” presentBoston, Massachusetts, United States
  7. The Column GroupVenture Partner2021 β€” 2023
  8. Remix TherapeuticsBoard Membercurrent2023 β€” present
  9. AviadoBioChaircurrent2023 β€” present
  10. KallyopeBoard Membercurrent2022 β€” present
  11. Topo TherapeuticsBoard Member2024 β€” 2026
  12. Atavistik BioBoard Member2021 β€” 2026Cambridge, Massachusetts, United States
  13. Atavistik BioInterim CEO2022 β€” 2023
  14. Ribon TherapeuticsBoard Member2021 β€” 2024Cambridge, MA
  15. Surface Oncology Inc.Board Member2018 β€” 2023Cambridge, Massachusetts, United States
  16. Surface Oncology Inc.CEO2018 β€” 2021Cambridge, MA
  17. Surface Oncology Inc.CBO2017 β€” 2018Cambridge, MA
  18. LogicBio TherapeuticsBoard Member2020 β€” 2022Lexington, Massachusetts, United States
  19. VaccinexBoard Member2013 β€” 2022
  20. Voyager Therapeutics, Inc.CFO2016Cambridge, MA

Education

  1. University of Rochester - Simon Business SchoolMBA
  2. University of Rochester School of Medicine and DentistryMS, Microbiology / Immunology
  3. University of Rochester School of Medicine and DentistryMS, Pathology
  4. University of RochesterBA, Biology

Skills & more

Corporate Finance8Start-ups9Corporate Development15Valuation6Mergers & Acquisitions27Due Diligence12Business Development23Licensing2Venture Capital7Investment Banking4M&A experience2Emerging Markets1
+4 morePrivate EquityIPOFinancial ModelingBiotechnology

From Jeff's professional profile.

Same school

Shared employers

Deals Β· 2

RYNE Biotechnology Inc.Board seat

via The Column Group Β· filed Mar 2024 Β· $81.8M raise

Ribon TherapeuticsBoard seat

via The Column Group Β· filed Dec 2022 Β· $25M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at The Column Group

Network2

Investors connected to Jeff in public investor directories β€” a warm-intro map.